Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer.
- Resource Type
- Academic Journal
- Authors
- Dorff TB; Department of Medical Oncology and Developmental Therapeutics, City of Hope National Medical Center, Duarte, California, USA.; Stein C; Department of Medical Oncology and Developmental Therapeutics, City of Hope National Medical Center, Duarte, California, USA.; Kortylewski M; Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.; Posadas E; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.; Synold T; Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.; Quinn D; Department of Medicine, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
- Source
- Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 9605408 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8852 (Electronic) Linking ISSN: 10849785 NLM ISO Abbreviation: Cancer Biother Radiopharm Subsets: MEDLINE
- Subject
- Language
- English
The effects of radium-223 on the immune system and the bone tumor microenvironment are incompletely understood. The authors describe mechanisms by which radium-223 may interact with the immune system, specifically through STAT-3 and impact on tumor and circulating lymphocyte populations. They review mechanisms through which effects of radium-223 and androgen-targeted therapy on bone microenvironment could be better elucidated. These knowledge gaps currently limit development of optimal combination therapy approaches for radium-223. Tissue based studies are currently underway in a prospective clinical trial to enhance therapeutic perspective on radium-223 treatment in the prostate cancer landscape.